SCYNEXIS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SCYNEXIS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $257.0K | Mar 13, 2018 |
| FY2016 | Dec 31, 2016 | $65.0K | Mar 13, 2017 |
| FY2016 | Sep 30, 2016 | $64.0K | Mar 13, 2017 |
| FY2016 | Jun 30, 2016 | $64.0K | Mar 13, 2017 |
| FY2016 | Mar 31, 2016 | $64.0K | Mar 13, 2017 |
| FY2016 | Dec 31, 2015 | $64.0K | Mar 13, 2017 |
| FY2016 | Sep 30, 2015 | $64.0K | Mar 13, 2017 |
| FY2016 | Jun 30, 2015 | $64.0K | Mar 13, 2017 |
| FY2016 | Mar 31, 2015 | $65.0K | Mar 13, 2017 |
| FY2016 | Dec 31, 2014 | $1.26M | Mar 13, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.60M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $3.75M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $140.14M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $5.09M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $13.16M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $121.0K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $257.0K | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $257.0K | Mar 14, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $11.74M | Mar 30, 2015 |
| FY2014 | Dec 31, 2013 | $9.57M | Mar 30, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $3.58M | Mar 30, 2015 |
| FY2014 | Dec 31, 2013 | $552.0K | Mar 30, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.61M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($21.29M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $67.04M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($62.81M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($32.87M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($55.19M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($53.71M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($12.47M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($25.06M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($29.99M) | Mar 13, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($16.07M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($37.12M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $72.67M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($85.76M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($60.84M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($51.15M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($48.92M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($29.98M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($26.32M) | Mar 14, 2019 |
| FY2016 | Dec 31, 2016 | ($5.63M) | Mar 13, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.28M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $26.41M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $30.93M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $27.26M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $23.77M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $36.52M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $38.39M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $21.56M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $18.33M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $20.08M | Mar 13, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.40M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $14.46M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $20.92M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $62.96M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $49.92M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $14.63M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $10.65M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $8.68M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $8.25M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $8.00M | Mar 13, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.28M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($24.01M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $60.16M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($79.88M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($54.56M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($49.35M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($38.12M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($28.32M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($24.56M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($29.35M) | Mar 13, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $0 | Mar 29, 2022 |
| FY2021 | Dec 31, 2020 | $4.0K | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $565.0K | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $2.0K | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $27.0K | Mar 13, 2018 |
| FY2016 | Dec 31, 2015 | $589.0K | Mar 13, 2017 |
| FY2016 | Dec 31, 2014 | $704.0K | Mar 13, 2017 |
| FY2014 | Dec 31, 2013 | $431.0K | Mar 30, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.03M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $90.64M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $128.41M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $87.81M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $119.84M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $102.54M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $57.15M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $53.17M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $45.85M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $59.79M | Mar 13, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.65M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $35.57M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $55.45M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $84.58M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $78.58M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $79.78M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $44.26M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $21.95M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $24.44M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $24.97M | Mar 13, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.38M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $55.08M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $72.96M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $3.23M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $41.26M | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | $22.76M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $12.90M | Mar 29, 2022 |
| FY2020 | Dec 31, 2018 | $31.23M | Mar 29, 2021 |
| FY2019 | Dec 31, 2017 | $21.41M | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | $34.82M | Mar 14, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($385.14M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($376.54M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($355.25M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($422.29M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($359.48M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($326.61M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($271.43M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($217.72M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($205.25M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($180.12M) | Mar 13, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.26M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $16.05M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $34.05M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $45.81M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $104.48M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $93.04M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $41.92M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $11.44M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $11.47M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $35.66M | Mar 13, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2021 | $34.39M | Mar 31, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | 1 | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 31, 2023 |
| FY2016 | Dec 31, 2016 | (1) | Mar 13, 2017 |
| FY2016 | Dec 31, 2015 | (2) | Mar 13, 2017 |
| FY2016 | Dec 31, 2014 | (1) | Mar 13, 2017 |
| FY2014 | Dec 31, 2013 | (139) | Mar 30, 2015 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | 1 | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 31, 2023 |
| FY2016 | Dec 31, 2016 | (1) | Mar 13, 2017 |
| FY2016 | Dec 31, 2015 | (2) | Mar 13, 2017 |
| FY2016 | Dec 31, 2014 | (2) | Mar 13, 2017 |
| FY2014 | Dec 31, 2013 | (139) | Mar 30, 2015 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 43.54M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 37.97M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | 37.21M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | 32.68M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 28.71M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 19.66M | Mar 29, 2022 |
| FY2021 | Jul 17, 2020 | 10.51M | Mar 29, 2022 |
| FY2021 | Jul 16, 2020 | 105.08M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | 9.74M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | 47.97M | Mar 11, 2020 |